It would be tough for FDA to track whether a traditional compounding facility, which is not required to register with the agency, is limiting its compounding of drugs to specific indications, said an FDA official at a Pharmacy Compounding Advisory Committee meeting Tuesday (Feb. 24). The comment came up as the committee weighed whether to add six drugs to a list of bulk drugs that, when compounded by a traditional compounder, would be exempted from key FDA drug law requirements...